These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 31361272)

  • 21. Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.
    Braun DL; Scheier T; Ledermann U; Flepp M; Metzner KJ; Böni J; Günthard HF
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33228206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
    Kagan RM; Dunn KJ; Snell GP; Nettles RE; Kaufman HW
    AIDS Res Hum Retroviruses; 2019 Aug; 35(8):698-709. PubMed ID: 31169022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.
    Akil B; Blick G; Hagins DP; Ramgopal MN; Richmond GJ; Samuel RM; Givens N; Vavro C; Song IH; Wynne B; Ait-Khaled M;
    Antivir Ther; 2015; 20(3):343-8. PubMed ID: 25321146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.
    Blanco JL; Rojas J; Paredes R; Negredo E; Mallolas J; Casadella M; Clotet B; Gatell JM; de Lazzari E; Martinez E;
    J Antimicrob Chemother; 2018 Jul; 73(7):1965-1971. PubMed ID: 29608685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort.
    Abdullahi A; Kida IM; Maina UA; Ibrahim AH; Mshelia J; Wisso H; Adamu A; Onyemata JE; Edun M; Yusuph H; Aliyu SH; Charurat M; Abimiku A; Abeler-Dorner L; Fraser C; Bonsall D; ; Kemp SA; Gupta RK
    J Antimicrob Chemother; 2023 Aug; 78(8):2000-2007. PubMed ID: 37367727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 subtype-specific drug resistance on dolutegravir-based antiretroviral therapy: protocol for a multicentre study (DTG RESIST).
    Egger M; Sauermann M; Loosli T; Hossmann S; Riedo S; Beerenwinkel N; Jaquet A; Minga A; Ross J; Giandhari J; Kouyos RD; Lessells R
    BMJ Open; 2024 Aug; 14(8):e085819. PubMed ID: 39174068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recycling Tenofovir in Second-line Antiretroviral Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeks.
    Keene CM; Cassidy T; Zhao Y; Griesel R; Jackson A; Sayed K; Omar Z; Hill A; Ngwenya O; Van Zyl G; Flowers T; Goemaere E; Maartens G; Meintjes G
    J Acquir Immune Defic Syndr; 2023 Apr; 92(5):422-429. PubMed ID: 36706364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
    Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S;
    Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
    Aboud M; Orkin C; Podzamczer D; Bogner JR; Baker D; Khuong-Josses MA; Parks D; Angelis K; Kahl LP; Blair EA; Adkison K; Underwood M; Matthews JE; Wynne B; Vandermeulen K; Gartland M; Smith K
    Lancet HIV; 2019 Sep; 6(9):e576-e587. PubMed ID: 31307948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in pediatrics.
    Fokam J; Nka AD; Mamgue Dzukam FY; Efakika Gabisa J; Bouba Y; Tommo Tchouaket MC; Ka'e AC; Ngoufack Jagni Semengue E; Takou D; Moudourou S; Fainguem N; Pabo W; Nayang Mundo RA; Kengni Ngueko AM; Ambe Chenwi C; Flore Yimga J; Nnomo Zam MK; Simo Kamgaing R; Tangimpundu C; Kamgaing N; Njom-Nlend AE; Ndombo Koki P; Kesseng D; Ndiang Tetang S; Kembou E; Ebiama Lifanda L; Pamen B; Ketchaji A; Saounde Temgoua E; Billong SC; Zoung-Kanyi Bissek AC; Hadja H; Halle EG; Colizzi V; Perno CF; Sosso SM; Ndjolo A
    Medicine (Baltimore); 2023 May; 102(20):e33737. PubMed ID: 37335723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana.
    Seatla KK; Maruapula D; Choga WT; Ntsipe T; Mathiba N; Mogwele M; Kapanda M; Nkomo B; Ramaabya D; Makhema J; Mmalane M; Mine M; Kasvosve I; Lockman S; Moyo S; Gaseitsiwe S
    Viruses; 2021 Mar; 13(4):. PubMed ID: 33807382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study.
    Lagi F; Baldin G; Colafigli M; Capetti A; Madeddu G; Kiros ST; Di Giambenedetto S; Sterrantino G
    Int J Antimicrob Agents; 2019 Oct; 54(4):487-490. PubMed ID: 31195121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO.
    Mboumba Bouassa RS; Mossoro-Kpinde CD; Gody JC; Veyer D; Péré H; Matta M; Robin L; Grésenguet G; Charpentier C; Bélec L
    J Antimicrob Chemother; 2019 Jul; 74(7):2030-2038. PubMed ID: 30891603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adherence and preexisting major protease inhibitor resistance mutations are associated with virologic failure of a dual-class antiretroviral regimen with inhibitors of HIV-1 viral protease and integrase.
    Gardner EM; Melendez AG; Astiz M; Bray K
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(1):34-9. PubMed ID: 21972263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of virological failure in HIV-1-infected patients switching to dolutegravir maintenance monotherapy.
    Wijting I; Rutsaert SL; Rokx C; Burger DM; Verbon A; van Kampen J; Boucher C; Rijnders B; Vandekerckhove L
    HIV Med; 2019 Jan; 20(1):63-68. PubMed ID: 30270543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.
    Boffito M; Waters L; Cahn P; Paredes R; Koteff J; Van Wyk J; Vincent T; Demarest J; Adkison K; Quercia R
    AIDS Res Hum Retroviruses; 2020 Jan; 36(1):13-18. PubMed ID: 31507204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
    Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
    Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
    Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
    Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.
    ; Kouanfack C; Mpoudi-Etame M; Omgba Bassega P; Eymard-Duvernay S; Leroy S; Boyer S; Peeters M; Calmy A; Delaporte E
    N Engl J Med; 2019 Aug; 381(9):816-826. PubMed ID: 31339676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.